322 related articles for article (PubMed ID: 22400044)
21. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
Neckers L; Neckers K
Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
[TBL] [Abstract][Full Text] [Related]
22. Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design.
Verkhivker GM; Dixit A; Morra G; Colombo G
Curr Top Med Chem; 2009; 9(15):1369-85. PubMed ID: 19860735
[TBL] [Abstract][Full Text] [Related]
23. HSP90: a rising star on the horizon of anticancer targets.
Dai C; Whitesell L
Future Oncol; 2005 Aug; 1(4):529-40. PubMed ID: 16556029
[TBL] [Abstract][Full Text] [Related]
24. An update on the status of HSP90 inhibitors in cancer clinical trials.
Rastogi S; Joshi A; Sato N; Lee S; Lee MJ; Trepel JB; Neckers L
Cell Stress Chaperones; 2024 Jun; 29(4):519-539. PubMed ID: 38878853
[TBL] [Abstract][Full Text] [Related]
25. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
26. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
27. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
28. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
29. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Soga S; Akinaga S; Shiotsu Y
Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
[TBL] [Abstract][Full Text] [Related]
30. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
Hwang M; Moretti L; Lu B
Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
[TBL] [Abstract][Full Text] [Related]
31. Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain.
Terracciano S; Russo A; Chini MG; Vaccaro MC; Potenza M; Vassallo A; Riccio R; Bifulco G; Bruno I
Sci Rep; 2018 Jan; 8(1):1709. PubMed ID: 29374167
[TBL] [Abstract][Full Text] [Related]
32. HSP90 as a platform for the assembly of more effective cancer chemotherapy.
Whitesell L; Lin NU
Biochim Biophys Acta; 2012 Mar; 1823(3):756-66. PubMed ID: 22222203
[TBL] [Abstract][Full Text] [Related]
33. The heat shock protein 90 chaperone complex: an evolving therapeutic target.
Barginear MF; Van Poznak C; Rosen N; Modi S; Hudis CA; Budman DR
Curr Cancer Drug Targets; 2008 Sep; 8(6):522-32. PubMed ID: 18781898
[TBL] [Abstract][Full Text] [Related]
34. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
35. Old and New Approaches to Target the Hsp90 Chaperone.
Sanchez J; Carter TR; Cohen MS; Blagg BSJ
Curr Cancer Drug Targets; 2020; 20(4):253-270. PubMed ID: 31793427
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in Hsp90 inhibitors as antitumor agents.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Anticancer Agents Med Chem; 2008 Oct; 8(7):761-82. PubMed ID: 18855578
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
38. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 90.
Neckers L; Ivy SP
Curr Opin Oncol; 2003 Nov; 15(6):419-24. PubMed ID: 14624223
[TBL] [Abstract][Full Text] [Related]
40. Hsp90: still a viable target in prostate cancer.
Centenera MM; Fitzpatrick AK; Tilley WD; Butler LM
Biochim Biophys Acta; 2013 Apr; 1835(2):211-8. PubMed ID: 23287571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]